SMTISanara MedTech Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~22% a year FCF growth. Roughly in line with its three-year revenue growth of 23% a year.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SMTI's price assumes
Sanara MedTech Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.87× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.5%
Free cash flow yield · Medical Instruments & Supplies median 3.6%
- Growth the price implies
- +22%
Growth the price implies · The price pays for +22% free cash flow growth a year for a decade; revenue has grown 23% a year over the last three.
- Price / book
- 25.9
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 25.9
- EV / EBITas of 2026-Q2
- 28.1
- EV / salesas of 2026-Q2
- 2.15
- Free cash flow, trailing twelve months
- $4.5M
- Market capitalisation9.2 million shares, counted Aug 7, 2026
- $302M
- 3-year revenue growth
- +23%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Medical Instruments & Supplies
Ranks #13 of 20 by RyuScore